CYPHERPUNK TECHNOLOGIES INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $16.00K, a 44.83% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for fiscal 2025 was $16.00K, a 82.61% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for fiscal 2024 was $92.00K.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for fiscal 2021 was $4.00K, a 92.16% decline from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, stock options exercised for fiscal 2020 was $51.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $16.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $79.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $79.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-14 | $79.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $92.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | |
| 2024-03-31 | $29.00K 10-Q · filed 2025-05-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $4.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $40.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $4.00K 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $51.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-06-30 | $39.00K 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-14 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $14.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $14.00K 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $14.79M 10-Q/A · filed 2018-08-08 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $20.00K 10-K · filed 2019-04-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |